Leadership Growth New executive leadership (Chair/CEO and COO) signals a strategic push toward partnerships and scaled operations. Leverage their industry networks to engage large pharma, CROs, and academic collaborators for RLS-0071 co-development or licensing deals.

Inflammation Focus RLS-0071 is a dual-targeting agent that blocks both complement- and neutrophil-mediated inflammation, offering potential across inflammation-driven diseases such as acute graft-versus-host disease. Identify transplant centers, hematology-oncology networks, and rare-disease consortia as collaboration targets.

Funding Momentum Recent financing activity including a $40M round demonstrates investor confidence and can support late-stage validation and manufacturing scale-up. Use this momentum to open conversations with strategic partners on milestone-driven co-development or licensing opportunities.

Clinical Progress Phase 2 data for RLS-0071 in steroid-refractory aGvHD presented at ASH 2025 highlights target engagement and rapid clinical signals, providing a strong entry point for BD outreach to immunology and transplant-focused partners.

Commercial Readiness With a lean team and a growing leadership bench, ReAlta is well-positioned to pursue co-development, licensing, or strategic investments with mid- to large-sized pharma; tailor outreach to inflammation, immunology, and transplant portfolios and propose clear milestones.